Impact of the Latest Clinical Data among Patients with Breast Cancer in Low- and Middle-Income Countries

dc.contributor.author	Dawood, Shaheenah
dc.date.accessioned	2023-05-09T05:38:44Z
dc.date.available	2023-05-09T05:38:44Z
dc.date.issued	2022-12
dc.identifier.other	204-2022.211 Shaheenah Dawood
dc.identifier.uri	https://repository.mbru.ac.ae/handle/1/1250
dc.description.abstract	Introduction: In June 2022, experts from the oncology world gathered in Chicago, Illinois, for the American Society of Clinical Oncology (ASCO) 2022 annual meeting. In this article, we review the latest advancements presented at the conference regarding metastatic breast cancer [1]. Then, with experts in the field, we discuss the scientific findings from the studies presented and the practical implications of these data among breast cancer patients in low- and middle-income countries.	en_US
dc.language.iso	en	en_US
dc.subject	ASCO	en_US
dc.subject	Palbociclib	en_US
dc.subject	Sacituzumab	en_US
dc.subject	Trastuzumab	en_US
dc.subject	Pembrolizumab	en_US
dc.subject	Denosumab	en_US
dc.title	Impact of the Latest Clinical Data among Patients with Breast Cancer in Low- and Middle-Income Countries	en_US
dc.type	Article	en_US